The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Pancreatic Cancer Chemoresistance to Gemcitabine
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer, ranks among the leading causes of cancer-related deaths in the Western world due to disease presentation at an advanced stage, early metastasis and generally a very limited response to chemotherapy or radiotherapy. Gemcitabine remains a cornerstone of PDAC treatment in all stages of the disease despite suboptimal clinical effects primarily caused by molecular mechanisms limiting its cellular uptake and activation and overall efficacy, as well as the development of chemoresistance within weeks of treatment initiation. To circumvent gemcitabine resistance in PDAC, several novel therapeutic approaches, including chemical modifications of the gemcitabine molecule generating numerous new prodrugs, as well as new entrapment designs of gemcitabine in colloidal systems such as nanoparticles and liposomes, are currently being investigated. Many of these approaches are reported to be more efficient than the parent gemcitabine molecule when tested in cellular systems and in vivo in murine tumor model systems; however, although promising, their translation to clinical use is still in a very early phase. This review discusses gemcitabine metabolism, activation and chemoresistance entities in the gemcitabine cytotoxicity pathway and provides an overview of approaches to override chemoresistance in pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 2×
“In acquired resistance, tumor cells might show drug sensitivity in the beginning of treatment, but continued treatment ultimately leads to refractoriness to chemotherapy [30].”
BackgroundDelivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“For example, in various genetically-engineered mouse tumor models, pharmacologically-induced stroma remodeling [40,41] or enzyme-mediated degradation of stromal hyaluronan and collagen [42,43], resulted in increased drug delivery and responses to gemcitabine treatment.”
BackgroundFeig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 2×
“Other studies have indicated that T-cell-mediated immune therapy has beneficial effects despite remodeling of the stoma, including fibroblast depletion [46,47].”
BackgroundResultStromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Sherman, M. H., Yu, R. T., Engle, D. D., Ding, N., Atkins, A. R., Tiriac, H., Collisson, E. A., Connor, F., Van Dyke, T., Kozlov, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.007 · Cited by 1,158
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
Maeda, H. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100070g · Cited by 998
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1991) · PubMed · Cited by 876
Cellular pharmacology of gemcitabine
Mini, E., Nobili, S., Caciagli, B., Landini, I., & Mazzei, T. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj941 · Cited by 842
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese, J. L., Grunewald, R., Weeks, E. A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., Satterlee, W., & Raber, M. N. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.491 · Cited by 759
Stromal biology and therapy in pancreatic cancer
Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., et al. (2011) · Gut · doi:10.1136/gut.2010.226092 · Cited by 757
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C., & Grindey, G. B. (1990) · PubMed · Cited by 680
The role of stroma in pancreatic cancer: Diagnostic and therapeutic implications
Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J., & Friess, H. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.115 · Cited by 662
Mackey, J. R., Mani, R. S., Selner, M., Mowles, D., YOUNG, J., Belt, J. A., Crawford, C. R., & Cass, C. E. (1998) · PubMed · Cited by 599
de Sousa Cavalcante, L., & Monteiro, G. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.041 · Cited by 576
Farrell, J. J., Elsaleh, H., Garcia, M., Lai, R., Ammar, A., Regine, W. F., Abrams, R., Benson, A. B., Macdonald, J., Cass, C. E., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.067 · Cited by 458
A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment
Apte, M. V., Wilson, J. S., Lugea, A., & Pandol, S. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.11.037 · Cited by 450
Spratlin, J., Sangha, R., Glubrecht, D., Dabbagh, L., Young, J. D., Dumontet, C., Cass, C., Lai, R., & Mackey, J. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0224 · Cited by 430
Frese, K. K., Neesse, A., Cook, N., Bapiro, T. E., Lolkema, M. P., Jodrell, D. I., & Tuveson, D. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0242 · Cited by 415
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Binenbaum, Y., Na’ara, S., & Gil, Z. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.002 · Cited by 414
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Heinemann, V, Xu, Y. Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., & Plunkett, W. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09518-5 · Cited by 399
The role of stromal cancer-associated fibroblasts in pancreatic cancer
von Ahrens, D., Bhagat, T. D., Nagrath, D., Maitra, A., & Verma, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0448-5 · Cited by 389
Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent
Patra, C. R., Bhattacharya, R., Wang, E., Katarya, A., Lau, J. S., Dutta, S., Muders, M., Wang, S., Buhrow, S. A., Safgren, S. L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6102 · Cited by 371
Pancreatic cancer: understanding and overcoming chemoresistance
Wang, Z., Li, Y., Ahmad, A., Banerjee, S., Azmi, A. S., Kong, D., & Sarkar, F. H. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.188 · Cited by 364
The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29
Young, J. D., Yao, S. Y. M., Baldwin, J. M., Cass, C. E., & Baldwin, S. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.05.007 · Cited by 356
Giovannetti, E., Del Tacca, M., Mey, V., Funel, N., Nannizzi, S., Ricci, S., Orlandini, C., Boggi, U., Campani, D., Del Chiaro, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4203 · Cited by 351
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., Garner, E., Campbell, F., Mackey, J. R., Costello, E., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt347 · Cited by 337
Nakano, Y., Tanno, S., Koizumi, K., Nishikawa, T., Nakamura, K., Minoguchi, M., Izawa, T., Mizukami, Y., Okumura, T., & Kohgo, Y. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603559 · Cited by 328
Heinemann, V., Xu, Y.-Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1992) · PubMed · Cited by 328
Weizman, N., Krelin, Y., Shabtay-Orbach, A., Amit, M., Binenbaum, Y., Wong, R. J., & Gil, Z. (2014) · Oncogene · doi:10.1038/onc.2013.357 · Cited by 281
Wörmann, S. M., Song, L., Ai, J., Diakopoulos, K. N., Kurkowski, M. U., Görgülü, K., Ruess, D., Campbell, A., Doglioni, C., Jodrell, D., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.010 · Cited by 276
Immordino, M. L., Brusa, P., Rocco, F., Arpicco, S., Ceruti, M., & Cattel, L. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.09.001 · Cited by 251
Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., Pilarsky, C., Jodrell, D. I., Spong, S. M., & Tuveson, D. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300415110 · Cited by 246
Maréchal, R., Bachet, J., Mackey, J. R., Dalban, C., Demetter, P., Graham, K., Couvelard, A., Svrcek, M., Bardier–Dupas, A., Hammel, P., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.006 · Cited by 241
Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications
Moysan, E., Bastiat, G., & Benoit, J.-P. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300370t · Cited by 225 · cited 7×
“Phosphorylated metabolites of gemcitabine are reduced by cellular 5′-nucleotidase (5′-NT), and the monophosphate form dFdCMP is also converted and inactivated by deoxycytidylate deaminase (DCTD) into 2′-deoxy-2′,2′-difluorouridine monophosphate (dFdUMP) [60,61].”
BackgroundInfluentialPretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Kroep, J. R., Loves, W. J. P., van der Wilt, C. L., Álvarez, E., Talianidis, I., Boven, E., Braakhuis, B. J. M., van Groeningen, C. J., Pinedo, H. M., & Peters, G. J. (2002) · PubMed · Cited by 224
Maréchal, R., Mackey, J. R., Lai, R., Demetter, P., Peeters, M., Polus, M., Cass, C. E., Young, J., Salmon, I., Devière, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2080 · Cited by 219
Nielsen, M. F. B., Mortensen, M. B., & Detlefsen, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i9.2678 · Cited by 219
Bisht, S., Mizuma, M., Feldmann, G., Ottenhof, N. A., Hong, S.-M., Pramanik, D., Chenna, V., Karikari, C., Sharma, R., Goggins, M. G., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0172 · Cited by 216
Duluc, C., Moatassim‐Billah, S., Chalabi‐Dchar, M., Perraud, A., Samain, R., Breibach, F., Gayral, M., Cordelier, P., Delisle, M., Bousquet‐Dubouch, M., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404346 · Cited by 214
García-Manteiga, J. M., Molina‐Arcas, M., Casado, F. J., Mazo, A., & Pastor‐Anglada, M. (2003) · PubMed · Cited by 211
Nakahira, S., Nakamori, S., Tsujie, M., Takahashi, Y., Okami, J., Yoshioka, S., Yamasaki, M., Marubashi, S., Takemasa, I., Miyamoto, A., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22390 · Cited by 209
Hessmann, E., Patzak, M. S., Klein, L., Chen, N., Kari, V, Ramu, I., Bapiro, T. E., Frese, K. K., Gopinathan, A., Richards, F. M., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-311954 · Cited by 202
Stromnes, I. M., Schmitt, T. M., Hulbert, A., Brockenbrough, J. S., Nguyen, H. N., Cuevas, C., Dotson, A. M., Tan, X., Hotes, J. L., Greenberg, P. D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.022 · Cited by 200
Transport properties of pancreatic cancer describe gemcitabine delivery and response
Koay, E. J., Truty, M. J., Cristini, V., Thomas, R. M., Chen, R., Chatterjee, D., Kang, Y., Bhosale, P. R., Tamm, E. P., Crane, C. H., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73455 · Cited by 184 · cited 1×
“It is noteworthy that stromal content correlated with gemcitabine DNA incorporation only after accounting for levels of hENT1 [85].”
BackgroundCombinatorial Drug Conjugation Enables Nanoparticle Dual‐Drug Delivery
Aryal, S., Hu, C. J., & Zhang, L. (2010) · Small · doi:10.1002/smll.201000631 · Cited by 183
Costantino, C. L., Witkiewicz, A. K., Kuwano, Y., Cozzitorto, J. A., Kennedy, E. P., Dasgupta, A., Keen, J. C., Yeo, C. J., Gorospe, M., & Brody, J. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0371 · Cited by 181
Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players
Kim, M. P., & Gallick, G. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2247 · Cited by 177
Chaturvedi, P., Singh, A. P., Moniaux, N., Senapati, S., Chakraborty, S., Meza, J. L., & Batra, S. K. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0353 · Cited by 176
Arya, G., Vandana, M., Acharya, S., & Sahoo, S. K. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.03.009 · Cited by 174
Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
Dauer, P., Nomura, A., Saluja, A., & Banerjee, S. (2016) · Pancreatology · doi:10.1016/j.pan.2016.12.010 · Cited by 165
Labori, K. J., Katz, M. H. G., Tzeng, C. W., Bjørnbeth, B. A., Cvancarova, M., Edwin, B., Kure, E. H., Eide, T. J., Dueland, S., Buanes, T. A., et al. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1068445 · Cited by 163
Self-citationClinical pharmacology and pharmacogenetics of gemcitabine
Wong, A. L., Soo, R. A., Yong, W. P., & Innocenti, F. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902741828 · Cited by 163
Gandhi, V. V., & Plunkett, W. K. (1990) · PubMed · Cited by 162
Fujita, H., Ohuchida, K., Mizumoto, K., Itaba, S., Ito, T., Nakata, K., Yu, J., Kayashima, T., Souzaki, R., Tajiri, T., et al. (2010) · Neoplasia · doi:10.1593/neo.10458 · Cited by 160
Sebastiani, V., Ricci, F., Rubio-Viquiera, B., Kulesza, P., Yeo, C. J., Hidalgo, M., Klein, A., Laheru, D., & Iacobuzio-Donahue, C. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2655 · Cited by 160
Skrypek, N., Duchêne, B., Hebbar, M., Leteurtre, E., SEUNINGEN, I. V., & Jonckheere, N. (2012) · Oncogene · doi:10.1038/onc.2012.179 · Cited by 157
Achiwa, H., Oguri, T., Sato, S., 前田, 浩., Niimi, T., & Ueda, R. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03257.x · Cited by 157
Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint
Rueff, J., & Rodrigues, A. S. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3347-1_1 · Cited by 157
Ślusarczyk, M., Lopez, M. H., Balzarini, J. M., Mason, M. D., Jiang, W. G., Blagden, S. P., Thompson, E., Ghazaly, E. A., & McGuigan, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401853a · Cited by 153
Thymidylate Synthase: A Critical Target for Cancer Chemotherapy
Rose, M. G., Farrell, M. P., & Schmitz, J. C. (2002) · Clinical Colorectal Cancer · doi:10.3816/ccc.2002.n.003 · Cited by 151
Shipley, L. A., Brown, T. J., Cornpropst, J. D., Hamilton, M. L., Daniels, W. D., & Culp, H. W. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08805-1 · Cited by 148
Hidalgo, M. M., Plaza, C., Musteanu, M., Illei, P. B., Brachmann, C. B., Heise, C. C., Pierce, D. W., Lopez-Casas, P. P., Menéndez, C., Tabernero, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3222 · Cited by 141
Mallaredy, V., & Sahoo, S. K. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.08.010 · Cited by 140
Poon, C. J., He, C., Liu, D., Lu, K., & Lin, W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.026 · Cited by 136
Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions
Andersson, R. E., Aho, U., Nilsson, B. I., Peters, G. J., Pastor‐Anglada, M., Rasch, W., & Sandvold, M. L. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520902745039 · Cited by 136
Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes
Kadaba, R., Birke, H., Wang, J., Hooper, S., Andl, C. D., Maggio, F. D., Soylu, E., Ghallab, M., Bor, D., Froeling, F. E. M., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4172 · Cited by 131
Key role of pancreatic stellate cells in pancreatic cancer
Pothula, S. P., Xu, Z., Goldstein, D., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.035 · Cited by 131
Awasthi, N., Zhang, C., Schwarz, A. M., Hinz, S., Wang, C., Williams, N. S., Schwarz, M. A., & Schwarz, R. E. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt227 · Cited by 130
Stromal reengineering to treat pancreas cancer
Stromnes, I. M., DelGiorno, K. E., Greenberg, P. D., & Hingorani, S. R. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu115 · Cited by 130
Human Cytosolic 5′-Nucleotidase I
Hunsucker, S. A., Spychała, J., & Mitchell, B. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011218200 · Cited by 125
Allain, V., Bourgaux, C., & Couvreur, P. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr681 · Cited by 122
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells
Saiki, Y., Yoshino, Y., Fujimura, H., Manabe, T., Kudo, Y., Shimada, M., Mano, N., Nakano, T., Lee, Y., Shimizu, S., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.03.122 · Cited by 114
Stella, B., Arpicco, S., Rocco, F., Marsaud, V., Renoir, J., Cattel, L., & Couvreur, P. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.006 · Cited by 114
Bhutia, Y. D., Hung, S. W., Patel, B., Lovin, D., & Govindarajan, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2736 · Cited by 111
Ohhashi, S., Ohuchida, K., Mizumoto, K., Fujita, H., Egami, T., Yu, J., Toma, H., Sadatomi, S., Nagai, E., & Tanaka, M. (2008) · PubMed · Cited by 111
Hesler, R., Huang, J. J., Starr, M. D., Treboschi, V. M., Bernanke, A., Nixon, A. B., McCall, S. J., White, R. R., & Blobe, G. C. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw093 · Cited by 111
Nakai, Y., Isayama, H., Sasaki, T., Sasahira, N., Tsujino, T., Toda, N., Kogure, H., Matsubara, S., Ito, Y., Togawa, O., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.183 · Cited by 104
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles
Sloat, B. R., Sandoval, M. A., Li, D., Chung, W.-G., Lansakara-P, D. S. P., Proteau, P., Kiguchi, K., DiGiovanni, J., & Cui, Z. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.02.037 · Cited by 104
Réjiba, S., Reddy, L. H., Bigand, C., Parmentier, C., Couvreur, P., & Hajri, A. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.02.012 · Cited by 103
Richards, N. G., Rittenhouse, D. W., Freydin, B., Cozzitorto, J. A., Grenda, D. R., Rui, H., Gonye, G., Kennedy, E. P., Yeo, C. J., Brody, J. R., et al. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181f1fd44 · Cited by 102
Chitkara, D., Mittal, A., Behrman, S. W., Kumar, N., & Mahato, R. I. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400032x · Cited by 101
Fukunaga, A. K., Marsh, S., Murry, D. J., Hurley, T. D., & McLeod, H. L. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500259 · Cited by 99
Zhang, H., Wu, H., Guan, J., Wang, L., Ren, X., Shi, X., Liang, Z., & Liu, T. (2014) · Oncotarget · doi:10.18632/oncotarget.3099 · Cited by 96
Bergman, A. M., Adema, A. D., Balzarini, J. M., Bruheim, S., Fichtner, I., Noordhuis, P., Fodstad, Ø., Myhren, F., Sandvold, M. L., Hendriks, H. R., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-009-9377-7 · Cited by 96
Overcoming nucleoside analog chemoresistance of pancreatic cancer: A therapeutic challenge
Hung, S. W., Mody, H. R., & Govindarajan, R. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.007 · Cited by 88
Yu, X., Pu, X., Xie, C. L., Song, Y., He, H., Li, H., Lu, W., Fu, D., Jin, C., & Yang, D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s93835 · Cited by 83
Integrating pharmacogenetics into gemcitabine dosing—time for a change?
Ciccolini, J., Mercier, C., Dahan, L., & André, N. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.1 · Cited by 79
Réjiba, S., Bigand, C., Parmentier, C., & Hajri, A. (2009) · Neoplasia · doi:10.1593/neo.81686 · Cited by 78
Chemoresistance in pancreatic cancer: Emerging concepts
Gnanamony, M., & Gondi, C. S. (2017) · Oncology Letters · doi:10.3892/ol.2017.5777 · Cited by 72
Tjomsland, V., Pomianowska, E., Aasrum, M., Sandnes, D., Verbeke, C. S., & Gladhaug, I. P. (2016) · Neoplasia · doi:10.1016/j.neo.2016.06.003 · Cited by 71
Self-citationMolecular Events in the Natural History of Pancreatic Cancer
Oldfield, L. E., Connor, A. A., & Gallinger, S. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.005 · Cited by 71
Li, J., Chen, W., Wang, H., Jin, C., Yu, X., Lu, W., Cui, L., Fu, D.-L., Ni, Q.-X., & Hou, H.-M. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.125 · Cited by 68
Chung, W.-G., Sandoval, M. A., Sloat, B. R., Lansakara-P, D. S. P., & Cui, Z. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.004 · Cited by 68
Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Brusa, P., Immordino, M. L., Rocco, F., & Cattel, L. (2007) · PubMed · Cited by 68
Synthesis and characterization of TPGS–gemcitabine prodrug micelles for pancreatic cancer therapy
Khare, V. R., Al-Shakarchi, W., Gupta, P. N., Curtis, A. D. M., & Hoskins, C. (2016) · RSC Advances · doi:10.1039/c6ra09347g · Cited by 68
Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer
Dimou, A., Syrigos, K. N., & Saif, M. W. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012446008 · Cited by 66
Daman, Z., Ostad, S. N., Amini, M., & Gilani, K. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.04.021 · Cited by 65
Jonckheere, N., Skrypek, N., Merlin, J., Dessein, A., Dumont, P., Leteurtre, E., Harris, A., Desseyn, J., Susini, C., Frénois, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032232 · Cited by 65
Zhu, S., Wonganan, P., Lansakara-P, D. S. P., O’Mary, H. L., Li, Y., & Cui, Z. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.11.053 · Cited by 64
Utama, R. H., Jiang, Y., Zetterlund, P. B., & Stenzel, M. H. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00545 · Cited by 64
Bianchi, V., Borella, S., Calderazzo, F., Ferraro, P., Bianchi, L. C., & Reichard, P. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8403 · Cited by 60
Kim, H., Samuel, S. L., Lopez-Casas, P. P., Grizzle, W. E., Hidalgo, M. M., Kovar, J. L., Oelschlager, D. K., Zinn, K. R., Warram, J. M., & Buchsbaum, D. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0764 · Cited by 59
Jimbo, M., Blanco, F. F., Huang, Y.-H., Telonis, A. G., Screnci, B., Cosma, G. L., Alexeev, V. Y., Gonye, G. E., Yeo, C. J., Sawicki, J. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4743 · Cited by 56
A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer
Coppola, S., Carnevale, I., Danen, E. H. J., Peters, G. J., Schmidt, T., Assaraf, Y. G., & Giovannetti, E. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.07.001 · Cited by 56
Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug
Wu, W., Sigmond, J., Peters, G. J., & Borch, R. F. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070269u · Cited by 52
Synthesis and biological evaluation of gemcitabine–lipid conjugate (NEO6002)
Ali, S. M., Khan, A. R., Ahmad, M. U., Chen, P., Sheikh, S., & Ahmad, I. N. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.046 · Cited by 52
Tsume, Y., İnceçayır, T., Song, X., Hilfinger, J. M., & Amidon, G. L. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.12.009 · Cited by 51
Skrypek, N., Vasseur, R., Vincent, A., Duchêne, B., SEUNINGEN, I. V., & Jonckheere, N. (2015) · Oncotarget · doi:10.18632/oncotarget.3414 · Cited by 48
Goel, G., & Sun, W. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0141-5 · Cited by 46
Wang, C., Zhang, W., Fu, M., Yang, A., Huang, H., & Xie, J. (2014) · Oncology Reports · doi:10.3892/or.2014.3599 · Cited by 45
Maksimenko, A., Caron, J., Mougin, J., Desmaële, D., & Couvreur, P. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.11.009 · Cited by 45
Kong, X., Li, L., Li, Z., & Xie, K. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.06.006 · Cited by 44
Erkan, M. (2013) · The Journal of Pathology · doi:10.1002/path.4213 · Cited by 43
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine–cardiolipin conjugate
Chen, P., Chien, P.-Y., Khan, A. R., Sheikh, S., Ali, S. M., Ahmad, M. U., & Ahmad, I. N. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000185182.80227.48 · Cited by 42
Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer
Koay, E. J., Baio, F. E., Ondari, A., Truty, M. J., Vittorio Cristini, C., Thomas, R. M., Chen, R., Chatterjee, D., Kang, Y., Zhang, J., et al. (2014) · Physical Biology · doi:10.1088/1478-3975/11/6/065002 · Cited by 38
Ellenrieder, V., König, A. O., & Seufferlein, T. T. W. (2016) · Digestion · doi:10.1159/000447739 · Cited by 38
Al‐Batran, S., Geißler, M., Seufferlein, T. T. W., & Oettle, H. (2014) · Oncology Research and Treatment · doi:10.1159/000358890 · Cited by 34
Joubert, F., Martin, L., Perrier, S., & Pasparakis, G. (2017) · ACS Macro Letters · doi:10.1021/acsmacrolett.7b00160 · Cited by 33
Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer
Komori, S., Osada, S., Mori, R., Matsui, S., Sanada, Y., Tomita, H., Tokuyama, Y., Takahashi, T., Yamaguchi, K., & Yoshida, K. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181dec17d · Cited by 30
Fang, Y., Du, F., Xu, Y., Meng, H., Huang, J. T., Zhang, X., Lu, W. P., Liu, S., & Yu, J. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.02.028 · Cited by 28
Tsume, Y., Bermejo, B. B., & Amidon, G. L. (2014) · Pharmaceuticals · doi:10.3390/ph7020169 · Cited by 14
Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
Komori, S., Osada, S., & Yoshida, K. (2011) · ISRN Oncology · doi:10.5402/2011/936893 · Cited by 11
Cited by
Orth, M., Metzger, P., Gerum, S., Mayerle, J., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 490
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Metabolism of pancreatic cancer: paving the way to better anticancer strategies
Qin, C., Yang, G., Yang, J., Ren, B., Wang, H., Chen, G., Zhao, F., You, L., Wang, W., & Zhao, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01169-7 · Cited by 413
Tang, B., Yang, Y., Kang, M., Wang, Y., Wang, Y., Bi, Y., He, S., & Shimamoto, F. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1128-6 · Cited by 327
RetractedThe nuclear export protein XPO1 — from biology to targeted therapy
Azmi, A. S., Uddin, M. H., & Mohammad, R. M. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00442-4 · Cited by 279
Metadata
- Authors
- Amrutkar, M., & Gladhaug, I.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2017-11-16
- Volume
- 9
- Issue
- 11
- Pages
- 157
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2769094265
- Cited by
- 448
- References
- 132
- FWCI
- 15.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.